

LIMITED AUDIT REVIEW REPORT


Review Report To The Board of Directors,
JENBURKT PHARMACEUTICALS LTD,
Nirmala Apartments, 93, J.P.Road,
Andheri (W),
Mumbai - 400 058.

We have reviewed the accompanying statement of unaudited financial results of JENBURKT PHARMACEUTICALS LTD for the quarter ended on 30th June, 2012 (1st April, 2012 to 30th June, 2012), except for the disclosures regarding "Public Shareholding" and "Promoter" and "Promoter Group Shareholding" which have been traced from disclosures made by the management and have not been audited by us. This statement is the responsibility of the Company's management and has been approved by the Board of Directors. Our responsibility is to issue a report on these financial statements based on our review.

We conducted our review in accordance with the Revised Standard on Review Engagements 2400. "Engagements to Review Financial Statements", issued by the Institute of Chartered Accountants of India (ICAI). This Standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and, accordingly, we do not express an audit opinion.

Based on our review, nothing has come to our attention that causes us to believe that the accompanying financial statements do not give a true and fair view (or are not presented fairly, in all material respects) in accordance with Financial Reporting Standards.

For D.L.Arora & Co.
Chartered Accountants
Firm Regn No.: 100545W


Dilip Arora
Proprietor
M.No.: 036152

Place : Mumbai.

Date: 31/07/2012.



Statement of standalone Unaudited Financial Results for the 1st Quarter Ended 30/06/2012					
PART-I				(Rs. in Lacs)	
Sr. No.	Particulars	Quarter ended			Year ended
		30/06/2012	31/03/2012	30/06/2011	31/03/2012
		Unaudited	Audited	Unaudited	Audited
1	Income from Operations:				
	(a) Net Sales/Income from Operations (Net of Excise Duty)	1478.83	1541.71	1244.39	5947.87
	(b) Other Operating Income	0.00	33.09	0.00	33.95
	Total Income from Operations (Net)	1478.83	1574.80	1244.39	5981.82
2	Expenses:				
	(a) Cost of Materials Consumed	512.68	338.86	359.58	1917.93
	(b) Purchases of Stock in Trade	0.58	0.00	0.24	91.93
	(c) Changes in Inventories of Finished Goods, Work-in-progress and Stock-in-Trade	-36.61	15.07	53.88	-41.60
	(d) Employee benefits Expense	383.20	334.26	288.46	1268.89
	(e) Depreciation and amortisation Expense	24.00	42.38	24.00	121.77
	(f) Other Expenses	450.31	637.31	374.43	1797.62
	Total Expenses:	1334.16	1367.88	1100.59	5156.54
3	Profit from Operations before other income, finance cost and exceptional items (1-2)	144.67	206.92	143.80	825.28
4	Other Income	6.77	48.31	4.94	81.52
5	Profit from ordinary activities before finance costs and exceptional items (3+4)	151.44	255.23	148.74	906.80
6	Finance Cost	23.46	14.61	21.70	62.79
7	Profit from ordinary activities after finance cost but before exceptional items (5-6)	127.98	240.62	127.04	844.01
8	Exceptional Items	0.00	10.27	0.00	8.05
9	Profit from Ordinary activities before tax (7+8)	127.98	250.89	127.04	852.06
10	Tax Expense	45.00	77.54	35.00	252.54
11	Net Profit from ordinary activities after tax (9-10)	82.98	173.35	92.04	599.52
12	Extra ordinary items	0.00	0.00	0.00	0.00
13	Net Profit for the period (11+12)	82.98	173.35	92.04	599.52
14	Paid-up equity share capital (F. V. of Rs. 10/- each)	464.93	464.93	464.93	464.93
15	Reserve excluding Revaluation - Reserves as per Balance Sheet of previous accounting year	0.00	0.00	0.00	1405.58
16	Earnings per share (before and after extraordinary items) (not annualised)-Basic and Diluted	1.78	3.73	1.98	12.89

h

PART II : Information for the Quarter ended on 30.06.2012

A. PARTICULARS OF SHAREHOLDING					
1. Public Shareholding					
-	Number of Shares	2839468	2549497	2582252	2549497
-	Percentage of Shareholding	54.62	54.84	55.54	54.82
2. Promoter and promoter Group shareholding					
a) Pledged /Encumbered					
-	Number of Shares	0.00	0.00	0.00	0.00
-	Percentage of Shares (as a % of the total shareholding of promoter and promoter group)	0.00	0.00	0.00	0.00
-	Percentage of Shares (as a % of the total share capital of the Company)	0.00	0.00	0.00	0.00
b) Non encumbered					
-	Number of Shares	2109832	2100103	2067048	2100103
-	Percentage of Shares (as a % of the total shareholding of promoter and promoter group)	100.00	100.00	100.00	100.00
-	Percentage of Shares (as a % of the total share capital of the Company)	45.38	45.17	44.46	45.17


B	INVESTOR COMPLAINTS	Quarter ended (30/06/12)
	Pending at the beginning of the quarter	NIL
	Received during the quarter	NIL
	Disposed off during the quarter	NIL
	Remaining unresolved at the end of the quarter	NIL

Notes:

- 1 The above unaudited results were reviewed by the Audit Committee and taken on record by the Board of Directors of the Company at their respective meetings held on 31st July, 2012.
- 2 The Limited Review of the above results has been carried out by the statutory auditors.
- 3 Figures of previous quarters/year are regrouped/ rearranged, wherever necessary.
- 4 The Company is dealing exclusively in pharmaceuticals formulation business segment; hence segment wise presentation of financial result is not required.

 Mumbai, 31st July, 2012

For Jenburkt Pharmaceuticals Ltd.


 Uttam N. Bhuta
 (Chairman and Managing Director)

Page: 2 of 2